Randomized trial demonstrates quadrivalent HPV vaccine prevents viral infection and external genital lesions in males aged 16 to 26, indicating strong clinical protection.
Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age. (Funded by Merck and others; ClinicalTrials.gov number, NCT00090285.).
No takes yet. Share an insight, caveat, or question.
Giuliano et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: